Table 3 Associated constants of hs-gate.
From: Characterization of a novel LQT3 variant with a selective efficacy of mexiletine treatment
| Â | \({{\boldsymbol{V}}}_{{{\bf{h}}}_{{{\boldsymbol{s}}}_{{\boldsymbol{\tau }}}}}\) | \({{\boldsymbol{a}}}_{{{\bf{h}}}_{{\boldsymbol{s}}}}\) | \({{\boldsymbol{b}}}_{{{\bf{h}}}_{{\boldsymbol{s}}}}\) | \({{\boldsymbol{c}}}_{{{\bf{h}}}_{{\boldsymbol{s}}}}\) | \({{\boldsymbol{d}}}_{{{\bf{h}}}_{{\boldsymbol{s}}}}\) |
|---|---|---|---|---|---|
WT | −3.000 | 57.314 | 104.658 | 59.032 | 0.0 |
A1656D | −3.423 | 449.708 | 128.855 | 165.944 | 17.551 |
Mexiletine | −10.432 | 89.477 | 48.360 | 160.984 | 6.627 |
Flecainide | −10.138 | 9.198 | −15.989 | 362.571 | 17.084 |
Ranolazine | 6.126 | 91.069 | −103.071 | −84.140 | 5.697 |
